DK1498121T3 - Hidtil ukendt anvendelse af specifikke cyclolignaner - Google Patents

Hidtil ukendt anvendelse af specifikke cyclolignaner

Info

Publication number
DK1498121T3
DK1498121T3 DK04024370T DK04024370T DK1498121T3 DK 1498121 T3 DK1498121 T3 DK 1498121T3 DK 04024370 T DK04024370 T DK 04024370T DK 04024370 T DK04024370 T DK 04024370T DK 1498121 T3 DK1498121 T3 DK 1498121T3
Authority
DK
Denmark
Prior art keywords
hitherto unknown
cyclolignans
specific
unknown use
specific cyclolignans
Prior art date
Application number
DK04024370T
Other languages
English (en)
Inventor
Olle Larsson
Magnus Axelson
Original Assignee
Axelar Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axelar Ab filed Critical Axelar Ab
Application granted granted Critical
Publication of DK1498121T3 publication Critical patent/DK1498121T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
DK04024370T 2001-06-19 2002-06-19 Hidtil ukendt anvendelse af specifikke cyclolignaner DK1498121T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds
US30043101P 2001-06-26 2001-06-26
PCT/SE2002/001202 WO2002102804A1 (en) 2001-06-19 2002-06-19 New use of specific cyclolignans

Publications (1)

Publication Number Publication Date
DK1498121T3 true DK1498121T3 (da) 2009-12-14

Family

ID=20284528

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04024370T DK1498121T3 (da) 2001-06-19 2002-06-19 Hidtil ukendt anvendelse af specifikke cyclolignaner

Country Status (15)

Country Link
US (7) US20040167208A1 (da)
EP (5) EP2186513A1 (da)
JP (2) JP2004534078A (da)
KR (1) KR100940055B1 (da)
CN (3) CN100503611C (da)
AT (1) ATE441411T1 (da)
AU (2) AU2002314671B2 (da)
CA (2) CA2451047C (da)
DK (1) DK1498121T3 (da)
ES (1) ES2333014T3 (da)
NO (1) NO332642B1 (da)
NZ (2) NZ530290A (da)
PT (1) PT1498121E (da)
SE (1) SE0102168D0 (da)
WO (2) WO2002102805A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0203747D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
SG132683A1 (en) * 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
ATE384700T1 (de) 2004-03-12 2008-02-15 Analytecon Sa Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren
AU2005230818B2 (en) 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2009527551A (ja) * 2006-02-24 2009-07-30 アクセラー エービー ２型糖尿病の治療用および避妊薬としてのシクロリグナンの使用
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof
WO2009108857A2 (en) * 2008-02-27 2009-09-03 Combithera, Inc. Combination therapy for prostate cancer
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
WO2009143051A1 (en) * 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2010138686A1 (en) * 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
US7924203B2 (en) * 2009-06-12 2011-04-12 Analog Devices, Inc. Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5642283B2 (ja) * 2010-08-31 2014-12-17 アクセラー エービー シクロリグナンを調製するための新たな方法
BR112013008232A2 (pt) 2010-10-08 2019-09-24 Axelar Ab Polimorfo b de picropodofilina, polimorfo c de picropodofilina, polimorfo b de picropodofilina, polimorfo c de picropodofilina, método de tratamento de câncer, composição farmacêutica, kit de combinação de partes, método para a preparação de polimorfo b de picropodofilina, e método para a preparação de polimorfo c de picropodofilina
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP5892508B2 (ja) * 2011-05-23 2016-03-23 国立大学法人 鹿児島大学 抗腫瘍剤及びその製造方法
WO2013124382A1 (en) * 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of cardiovascular disorders
WO2013132262A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives
WO2013132263A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives for use in therapy
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
WO2014102889A1 (ja) * 2012-12-25 2014-07-03 国立大学法人鹿児島大学 抗腫瘍剤及びその製造方法
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP2994461B1 (en) 2013-05-10 2021-02-17 M. Alphabet 2, LLC. Methods of treating skin conditions using cyclolignan compounds
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN112759603B (zh) 2015-10-27 2022-09-09 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
CN110669054B (zh) * 2018-07-03 2022-04-26 南京药石科技股份有限公司 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途
KR102378151B1 (ko) * 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control
ATE68186T1 (de) 1984-12-28 1991-10-15 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
NO170760C (no) * 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
SE468213B (sv) * 1986-06-27 1992-11-23 Conpharm Ab Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit
JPH01501790A (ja) * 1986-11-19 1989-06-22 ケメックス　ファーマシューティカルズ，インコーポレイティド リポキシゲナーゼ阻害剤
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1075316A (zh) 1992-10-22 1993-08-18 布里斯托尔-米尔斯·斯奎布公司 表鬼臼毒中间体的制备方法
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
JPH09194368A (ja) * 1996-01-11 1997-07-29 Pola Chem Ind Inc ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤
US5726027A (en) 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
WO1999028347A1 (en) 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
EP1087801B1 (en) 1998-06-26 2002-01-16 Quanam Medical Corporation Topoisomerase inhibitors for prevention of restenosis
EP1251858B1 (en) 2000-01-20 2005-06-08 Supratek Pharma Inc. Podophyllotoxin compositions
ES2271120T3 (es) * 2000-11-20 2007-04-16 Song-Bae Kim Procedimiento para preparar derivados de 4'-desmetil-4'-o-sustituido-1- desoxipodofilotoxina y sus isomeros geometricos y composicion anticaancerosa que los comprende.
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
JP2006521377A (ja) 2003-03-27 2006-09-21 ランケナー インスティテュート フォー メディカル リサーチ 新型ｉｄｏ阻害剤とその使用方法
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds

Also Published As

Publication number Publication date
CA2455328A1 (en) 2002-12-27
NO332642B1 (no) 2012-11-26
EP1938819A3 (en) 2010-04-07
WO2002102805A1 (en) 2002-12-27
US8389747B2 (en) 2013-03-05
US7662851B2 (en) 2010-02-16
NO20035648L (no) 2004-02-18
AU2002311731C1 (en) 2009-09-03
SE0102168D0 (sv) 2001-06-19
CN100503611C (zh) 2009-06-24
ATE441411T1 (de) 2009-09-15
CA2451047A1 (en) 2002-12-27
EP2186513A1 (en) 2010-05-19
NO20035648D0 (no) 2003-12-17
US20080221207A1 (en) 2008-09-11
EP1938819A2 (en) 2008-07-02
EP1498121A1 (en) 2005-01-19
EP1938818A2 (en) 2008-07-02
CN101606929A (zh) 2009-12-23
US20060154982A1 (en) 2006-07-13
NZ530172A (en) 2004-12-24
CA2451047C (en) 2012-10-09
NZ530290A (en) 2005-05-27
US7709526B2 (en) 2010-05-04
EP1397369A1 (en) 2004-03-17
EP1498121B1 (en) 2009-09-02
JP5071910B2 (ja) 2012-11-14
US20090326248A1 (en) 2009-12-31
JP2005500300A (ja) 2005-01-06
CN1543466A (zh) 2004-11-03
KR20040007743A (ko) 2004-01-24
EP1938818A3 (en) 2010-04-07
AU2002311731B8 (en) 2009-10-29
US7629381B2 (en) 2009-12-08
AU2002311731B2 (en) 2009-02-26
CN1659171A (zh) 2005-08-24
ES2333014T3 (es) 2010-02-16
US7348358B2 (en) 2008-03-25
WO2002102804A1 (en) 2002-12-27
US20080119528A1 (en) 2008-05-22
PT1498121E (pt) 2009-12-04
KR100940055B1 (ko) 2010-02-04
CA2455328C (en) 2011-09-20
US20100216728A1 (en) 2010-08-26
JP2004534078A (ja) 2004-11-11
AU2002314671B2 (en) 2008-09-18
US20040167208A1 (en) 2004-08-26
WO2002102804A8 (en) 2004-05-13
US20040186169A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
DK1498121T3 (da) Hidtil ukendt anvendelse af specifikke cyclolignaner
EA200602170A1 (ru) Производные пиперидина, композиции на их основе, способы их применения
RS20060079A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
GB9625045D0 (en) Parasiticidal compounds
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
NZ514711A (en) Compounds useful as anti-inflammatory agents
MX277756B (es) Metodo para preparar 3-halo-4,5-dihidro -1h-pirazoles.
NO20045497L (no) Fremgangsmate for fremstilling av 5-(1,3-oksazol-2-yl)benzosyrederivater
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
CY1107481T1 (el) Εναντιοεκλεκτικη αλκυλιωση τρικυκλικων ενωσεων
SE0301202D0 (sv) New use and new compounds
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme
NO20053261L (no) Fremgangsmate for a fremstille 1-acetoksy-3- (substituert fenyl) propen-forbindelse.
DE50101861D1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
ES2185459B1 (es) Procedimiento para la obtencion de pantoprazol y compuestos intermedios para el mismo.
DK1156058T3 (da) Fremgangsmåde til fremstilling af (E,Z) 3-(2-aminoethoxyimino)-androstan-6,17-dion og analoger deraf
EP1253139A3 (en) Multioligoanilinated fullerenes
ATE275558T1 (de) 4-arylpiperidinderivate zur behandlung von pruritus
CY1107515T1 (el) Συνθεση ενδιαμεσων χρησιμων στην παρασκευη τρικυκλικων ενωσεων
UY26416A1 (es) Compuestos
NO20033049L (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1-metylpiperidin
SE0203746D0 (sv) New compounds
GB0003257D0 (en) Heterocyclic compounds and their therapeutic use
YU62302A (sh) Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila